Dexcom (DXCM) Gross Profit (2010 - 2026)

Dexcom (DXCM) has 17 years of Gross Profit data on file, last reported at $750.3 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 27.39% year-over-year to $750.3 million in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 20.2% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, up 14.92% from the prior year.
• Gross Profit for Q1 2026 stood at $750.3 million, down from $792.7 million in the prior quarter.
• Over the last five years, Gross Profit for DXCM reached as high as $792.7 million in Q4 2025 and fell as low as $398.1 million in Q1 2022.
• Historically, Gross Profit has averaged $597.8 million across 5 years, with a median of $593.8 million in 2024.
• Across the five-year window, Gross Profit retreated 4.73% in 2024 and advanced 27.39% in 2026, its largest moves.
• Year by year, Gross Profit stood at $541.3 million in 2022, then gained by 21.3% to $656.6 million in 2023, then fell by 0.12% to $655.8 million in 2024, then grew by 20.88% to $792.7 million in 2025, then retreated by 5.35% to $750.3 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $750.3 million in Q1 2026, $792.7 million in Q4 2025, and $731.4 million in Q3 2025.